FDA gives thumbs up to Agilentís CDx
July/August 2020

SANTA CLARA, Calif.—A new assay is joining the ranks of approved companion diagnostics, as Agilent Technologies Inc.’s PD-L1 IHC 28-8 pharmDx got the nod from the U.S. Food and Drug Administration for expanded use in non-small cell lung cancer (NSCLC). The assay helps to determine which patients with metastatic NSCLC might benefit from treatment with a combination regimen of Opdivo (nivolumab) and Yervoy (ipilimumab). Agilent developed this companion diagnostic in 2016 under a collaboration with Bristol-Myers Squibb, and it has been approved as a complementary diagnostic for other cancer types as well.
“The expanded use of PD-L1 IHC 28-8 pharmDx will give physicians in the USA critical information to inform first-line treatment decisions for patients with metastatic non-small cell lung cancer,” said Sam Raha, president of Agilent’s Diagnostics and Genomics Group.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.